Clinical Evaluation on Xiyanping Injection in the Treatment of Bronchopneumonia in Children Based on Meta‑Analysis

Objective: The aim of this study is to evaluate the effectiveness and safety of xiyanping injection (XYPI) in the treatment of children with bronchopneumonia. Methods:Asystematic and comprehensive search was conducted in the domestic and foreign electronic databases CNKI, SinoMed, VIP, WanFang DATA, PubMed, The Cochrane Library, Embase, Web of Science, Clinical?Trials.gov, and the search date ended on May 30, 2019. Inclusion criteria: (1) the types of studies included were randomized controlled trials; (2) the study participants were infants and children with a clear diagnosis of bronchopneumonia, without gender and ethnic restrictions; (3) the intervention test group was XYPI or the control group plus XYPI. The control group was routine treatment (RT) (basic treatment such as fever, cough and asthma, oxygen inhalation, anti?infection, maintaining water, electrolyte balance, etc.) or other Western medicine or RT + other Western medicine treatment. Except for XYPI, the two groups were consistent in intervention measures.According to the Cochrane Handbook, 5.1 evaluation standard and a meta?analysis of the final included studies was performed using RevMan 5.3 software. Results:Atotal of 57 studies were included, with a total sample size of 8454 cases, of which 4255 were in the experimental group and 4199 were in the control group. Meta?analysis results showed that (1) Total effective rate: XYPI group was better than the control group (relative risk [RRRT] = 1.25, 95% confidence interval [CI] [1.15, 1.36], P < 0.00001; RRRT + RBVI = 1.18, 95% CI [1.09, 1.29], P < 0.0001; RR antibiotic = 1.16, 95% CI [1.09, 1.24], P < 0.00001, RRRT + antibiotic = 1.22, 95% CI [1.16, 1.27], P < 0.00001); antipyretic time: XYPI group was better than the control group (mean difference [MDRT] = ?0.97, 95% CI [?1.17, ?0.76], P < 0.00001; MDRT + antibiotic = ?2.28, 95% CI [?2.88, ?1.67], P < 0.00001; MDRT + RBVI = ?1.51, 95% CI [?1.81, ?1.21], P < 0.00001; cough disappearing time: XYPI group was better than the control group (MDRT = ?1.37, 95% CI [?1.74, ?1.00], P < 0.00001; MDRT + antibiotic = ?1.71, 95% CI [?2.04, ?1.37], P < 0.00001; MDRT + RBVI = ?1.51, 95% CI [?2.15, ?0.86], P < 0.00001); disappearance time of lung rales: XYPI group was better than the control group (MDRT = ?1.11, 95% CI [?1.35, ?0.88], P < 0.00001; MDRT + RBVI = ?1.63, 95% CI [?2.23, ?1.03], P < 0.00001). The difference was statistically significant; (2) Of the 57 studies (a total of 8454 cases), 29 studies reported adverse reactions, of which 18 studies did not find adverse reactions, and 11 studies reported adverse reactions such as nausea, vomiting, and rash after medication in both groups. (3) The funnel chart indicated potential publication bias. Conclusion: Based on the existing clinical evidence, XYPI can have a certain effect on the treatment of children with bronchopneumonia, and it is not yet possible to conclude its safety evaluation. Moreover, due to the low quality of the included studies, this evidence is still used with cautious clinically.     

Clinical Effect of Tripterygium Glycosides Combined with Glucocorticoids in the Treatment of Refractory Nephrotic Syndrome Patients: A Systematic Review and Meta‑Analysis

The objective of this study is to evaluate the effectiveness and safety of Tripterygium glycosides combined with glucocorticoids for the treatment of refractory nephrotic syndrome (NS). Computer search of Chinese and English databases, including CNKI, VIP, Wan Fang Database, PubMed, Cochrane Library, Embase, and Sinomed, for randomized controlled trials (RCTs) of Tripterygium glycosides combined with glucocorticoids for refractory NS (RNS) was conducted. Meta?analysis was performed using RevMan5.3. Thirteen RCTs comprising 994 patients were included in the study. Tripterygium glycosides combined with glucocorticoids had a statistical significance on the effective rate (odds ratio [OR] =4.69, 95% confidence interval [CI] 3.29, 6.67, P < 0.00001), 24?h urine protein ( Weighted mean difference (MD) = ?0.57, 95% CI [?0.62, ?0.51], P < 0.00001), serum albumin (MD = 4.77,95% CI [4.30, 5.24], P < 0.00001), total serum protein (MD = 9.45, 95% CI [8.73, 10.17], P < 0.00001), urea nitrogen (MD = ?0.53, 95% CI [?0.90, ?0.17], P = 0.005), and serum creatinine (MD = ?8.45, 95% CI [?15.32, ?1.57], P = 0.02). There was no statisticalsignificance on adverse reactions(OR = 0.68, 95% CI [0.41, 1.12], P = 0.13). Tripterygium glycosides combined with glucocorticoids could improve clinical effective rate, reduce 24?h urine protein, improve serum albumin and total serum protein, and reduce urea nitrogen and serum creatinine levels in patients with RNS. However, the quality of the included literature is poor, and conclusion still needs further verification using larger samples and high?quality randomized, double?blind controlled trials.     

Meta‑analysis of Clinical Efficacy of Traditional Chinese Medicine in the Treatment of Aplastic Anemia

Background: The “Diagnosis and Treatment Guidelines for Chinese Medicine Internal Common Diseases” issued by the Chinese Institute of traditional Chinese medicine (TCM) offers many methods for the treatment of aplastic anemia (AA). However, there is a lack of corresponding evidence. Objective: The study aimed to evaluate the clinical efficacy of TCM in the treatment of AA, and provide evidence for the development of guidelines for the diagnosis and treatment of AA using TCM. Methods: Data of randomized or semi?randomized control trials of AA treatments with TCM were retrieved, and the selected literature was scored using the Jadad scale. The data were extracted, and RevMan 5.2.6 software was used for the meta?analysis. Results: Two studies on the treatment of AA using Liuwei Dihuang pills combined with compound Zaofan pill were included. The results of the meta?analysis showed that there were no statistically significant differences in the efficacy between Liuwei Dihuang pills combined with compound Zaofan pill and androgen in the treatment of AA (P = 0.65). However, there were less adverse reactions, including liver damage and the hirsutism of women, with the former than the latter (P < 0.05). Other studies on the treatment of AA with TCM did not include reports from clinical trials. Conclusion: TCM had a certain curative effect when used to treat AA. However, the quality of the literature is generally low, and the sample size is small, which makes the validation of the results poor. Further high?quality studies are needed to provide high?level evidence.     

Efficacy of Traditional Chinese Medicine in the Treatment of Rash Caused by Epidermal Growth Factor Receptor Inhibitors: A Frequency Statistics and Meta‑Analysis

Objective: The aim of this study is to evaluate the efficacy of Traditional Chinese Medicine (TCM) in the treatment of rash caused by epidermal growth factor receptor inhibitors (EGFRIs). Materials and Methods: Foreign language database (such as PubMed, Web of Science, Cochrane Library, EMBASE) and Chinese language database (such as China National Knowledge Infrastructure, VIP Database for Chinese Technical Periodicals [VIP], Wangfang, CBM disc) were searched for all trials of TCM in the treatment of rash caused by EGFRIs until January of 2019. We also looked through the references of relevant studies to supplement additional trials. The SPSS 25.0 was used for statistics of TCM with high frequency, and Review Manager 5.3 was used for meta-analysis. Results: A total of 22 studies were included in the study. We selected TCM whose frequency were >3.0%. They were Lonicera japonica（金银花）, Licorice Roots Northwest Origin（生甘草）, Cortex Dictamni（白鲜皮）, Radix Sophorae Flavescentis（苦参）, Schizonepeta（荆芥）, Saposhnikovia Divaricate（防风）. The meta?analysis revealed that the efficacy of TCM in treating EGFRIs?related rash was better than that of Western medicine or none. Conclusions: TCM could significantly relieve rash caused by EGFRIs, which is worth popularizing. Moreover, the mechanism deserves to be further explored.     

Therapeutic Effect of Jianpi Decoction Combined with Chemotherapy on Postoperative Treatment of Colorectal Cancer: A Systematic Review and Meta‑analysis

Objective: The purpose of this systematic review is to assess the therapeutic effect of Jianpi decoctions in Chinese herbal medicines(CHM) combined with chemotherapy on the postoperative treatment of colorectal cancer. Methods: Literatures were obtained from Wanfang database, CNKI, Pub Med, Cqvip, MEDLINE, Cochrane, CBM, and Springer LINK as well as other conference papers and theses. The search included all documents in English or Chinese published before September 2018. We selected randomized controlled trials based on specific criteria and the most important criteria were that Jianpi decoction should be applied in combination with chemotherapy on the postoperative treatment of colorectal cancer. Results: Publications in eight electronic databases were extensively searched and 20 trials were included for analysis eventually. A total of 1652 patients in total were enrolled in these studies. Among them, 879 patients received CHM and Western medicine combination therapy and another 773 participants only got Western medicine therapy. Compared with those patients receiving Western medicine alone, the survival rate of 1-year(odds ratio [OR] = 2.35, 95% confidence limit [Cl] = 1.30–4.28, P 0.05), 3-year(OR = 2.02, 95% Cl = 1.49–2.73, P 0.001), and 5-year survival rate(OR = 2.32, 95% Cl = 1.56–3.45, P 0.001) of patients in the group of Jianpi decoctions in CHM and chemotherapy combination has significantly increased. Moreover, results also showed positive effects on immunoregulation such as CD3~+(OR = 0.68, 95% confidence interval [CI] = 0.52–0.85, P 0.0001), CD4~+/CD8~+(OR = 0.77, 95% CI = 0.29–1.26, P 0.05). Side effects caused by chemotherapy such as nausea(OR = 0.35, 95% CI = 0.25–0.50, P 0.0001) and vomiting(OR = 0.32, 95% CI = 0.22–0.46, P 0.0001), diarrhea(OR = 0.42, 95% CI = 0.30–0.60, P 0.0001), as well as metastasis and recurrence(OR = 0.38, 95% CI = 0.24–0.61, P 0.001) were remarkably reduced. The quality of life(OR = 4.40, 95% Cl = 2.86–6.77, P 0.0001) has been improved. Moreover, there was no statistically significant bias in the overall studies. Conclusion: This systematic review suggests that Jianpi decoction in CHM can reduce the chemotherapy toxicity, enhance the patient's immunity, prolong their survival rate, improve their quality of life as well as prevent metastasis, and recurrence for patients in postoperative treatment of colorectal cancer.     

Chinese Herbal Medicine for the Treatment of Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome‑Associated Diarrhea: A Protocol for the Systematic Review and Meta‑Analysis of Randomized Clinical Trials

Diarrhea can occur at an early or advanced stage of acquired immunodeficiency syndrome (AIDS) as a usual symptom in people with human immunodeficiency virus (HIV) infection. While it is usually not fatal, it can influence patients’ quality of life seriously. It has shown to be efficacious and improves people’simmune statusto a certain extent to treat HIV/AIDS?related diarrhea on the basis ofsyndrome differentiation and treatment or Chinese herbs plus conventional treatment. Therefore, it may have a good application potential. Here, we outline a protocol for the systematic review of this health?care intervention, with the aim to evaluate the beneficial effects and safety of Traditional Chinese Medicine (TCM) for patients who suffer from HIV/AIDS?associated diarrhea. Randomized controlled trials that compare Chinese herbs with placebo or other effective treatments will be searched and included, in spite of publication status or language. The primary outcomes include diarrhea frequency and fecal character. The databases we will search as follows: China Science and Technology Journal Database (VIP), Chinese Biomedical Literature Database (SinoMed), Wanfang Data, China National Knowledge Infrastructure, PubMed and the CENTRAL in Cochrane Library. Two authors will respectively conduct the screening of trials, data extraction, and use the Cochrane risk of bias tool to assess the methodological quality. We will analyze the data and perform a meta-analysis if possible. We intend to identify potential therapeutic modalities that may be of benefit to inform clinical practice by supplying existing evidence of the helpful effects and safety of TCM to treat patients suffering from HIV/AIDS?associated diarrhea.     

Analysis of Acupuncture Treatment Characteristics of Insomnia in Ancient Times

运用计算机对93种古医籍中用针灸治疗失眠的内容进行统计,统计结果显示,古代治疗本证共涉及穴位65个,总计108穴次.常用穴位为公孙、胆俞、隐白、气海、天府、三阴交、阴陵泉、肺俞、液门、关元、阴交等.常用经络为膀胱经、脾经、任脉、胃经等.     

A Study on the Mechanism of Bruceine D in the Treatment of Non‑small Cell Lung Cancer H1299 Cells

Background: Non?small cell lung cancer (NSCLC) is considered one of the leading causes of cancer?related death. Despite the availability of drugsfor the treatment of NSCLC, the need for the development of novel agents with high efficiency and fewer adverse effectsremains unmet. The natural compound bruceine D (BD) is widely recognized for its notable anti?inflammatory, antiparasitic, and hypoglycemic activities. However, it is unclear whether BD can be used as a novel agent for NSCLC treatment. Materials and Methods: MTT and colony formation assays were used to assess the antiproliferative effect of BD on NSCLC cells. Wound healing and transwell assays were performed to determine the effect of BD on the migration and invasion of H1299 cells, respectively. Western blotting assay was used to detect the expression levels of proteins. Results:We demonstrated thatBD significantly inhibited the proliferation of H1299,A549, and H226 cells with respective IC50 values of 6.06 ± 0.52, 7.15 ± 0.90, and 7.21 ± 0.75 μM. In addition, BD suppressed colony formation of H1299 cells in a dose?dependent manner. Following treatment with BD, the migration and invasive capabilities of H1299 cells were significantly inhibited in a dose? and time?dependent manner. Moreover, the results of Western blotting demonstrated that BD treatment resulted in the upregulation of the protein expression of E?cadherin and downregulation of the expression of N?cadherin, twist, snail, integrin αv, integrin β4, matrix metalloproteinase-7, and β-catenin proteins. Conclusion: BD inhibits proliferation, migration, and invasion of NSCLC cells; therefore, BD may be considered for its potential in adjuvant therapy for NSCLC.     

尿毒清颗粒联合血管紧张素系统阻滞剂治疗糖尿病肾病的Meta分析

目的:系统评价尿毒清颗粒联合RAAS系统阻滞剂治疗糖尿病肾病的疗效.方法:运用计算机检索CNKI、万方、VIP、Pubmed、Embase及Cochrane Library中关于尿毒清颗粒联合RAAS系统阻滞剂治疗糖尿病肾病随机对照试验(RCT)的研究文献.采用RevMan5.3软件对符合本次研究的文献中所需要的数据进...     

肾糖颗粒对糖尿病肾病大鼠疗效的实验研究

目的通过中药肾糖颗粒对糖尿病大鼠的治疗作用,探讨其临床实验效果。方法采用高脂饲料喂养＋STZ腹腔注射方法制作糖尿病肾病大鼠模型。分为正常对照组、模型对照组、中药治疗组（肾糖颗粒）、西药治疗组（盐酸贝那普利）、中西药治疗组（肾糖颗粒＋盐酸贝那普利）,观察各组大鼠治疗前后一般情况,并测定治疗后空腹血糖,24h尿蛋白定量,尿微量白蛋白,α1-微球蛋白、β2-微球蛋白、尿转铁蛋白、尿视黄醇结合蛋白。结果经肾糖颗粒治疗8周后,大鼠一般状况较模型对照组改善较好,体质量增加。空腹血糖,与模型组比较,各治疗组显著降低;24h尿蛋白定量、尿微量白蛋白、α1-微球蛋白、β2-微球蛋白,各治疗组也分别显著低于模型组;尿转铁蛋白、尿视黄醇结合蛋白,各治疗组均分别显著低于模型组。结论肾糖颗粒对糖尿病肾病大鼠有治疗效果,可以改善其肾功能,延缓糖尿病的肾脏损伤。     

肾维宁冲剂为主治疗糖尿病肾病38例疗效观察

目的:观察肾维宁冲剂为主治疗糖尿病肾病的临床疗效。方法:将72例本病患者随机分为治疗组38例和对照组34例,对照组采用控制血糖、控制饮食和口服科素亚治疗,治疗组在对照组治疗的基础上加服肾维宁冲剂。结果:对照组总有效率为67.65%,治疗组总有效率为86.84%,两组比较,P<0.05;且治疗组在24h尿蛋白定量、放免尿β2-mg定量、TCH、TG、BUN、Scr等方面的改善情况均优于对照组(P<0.01)。结论:肾维宁冲剂为主治疗糖尿病肾病疗效较好。     

参芪降糖颗粒治疗糖尿病肾病Meta分析

目的：本研究旨在对公开发表的参芪降糖颗粒或胶囊治疗糖尿病肾病Meta分析,评价其疗效及安全性。方法：检索中国生物医学文献数据库（CBM）、PubMed、中国期刊全文数据（CNKI）、中文科技期刊全文数据库维普（VIP）、EMbase,检索时限均从建库时间至2015年6月。收集参芪降糖颗粒治疗糖尿病的随机对照试验。按照事先制定的入选与剔除标准筛选文献。然后逐一评价纳入研究的质量,提取有效数据,采用RevMan 5.2.7软件进行Meta分析。评价指标包括：总有效率、尿白蛋白排泄率（UAER）、尿素氮（BUM）、血肌酐（SCr）、24小时尿蛋白定量、空腹血糖。结果：纳入文献9篇,共624例患者。各研究基线资料具有可比性,均报道有随机方法。Meta分析结果显示：参芪降糖颗粒在总有效率较高[OR = 0.55,95％CI（0.39,0.78）,Z = 3.32,P = 0.000 9],可降低糖尿病肾病患者尿蛋白排泄率[WMD = -77.77,95％CI（-198.11,42.58）,Z = 1.27,P<0.000 01]、尿素氨[WMD = -0.40,95％CI（-1.65,0.85）,Z = 0.63,P = 0.53]和24 h尿蛋白定量检测结果[SMD = -154.09,95％CI（-360.00,-56.81）,Z = 1.47,P = 0.14]均优于常规治疗组;参芪降糖颗粒（胶囊）在降低血肌酐[WMD = -9.84,95％CI（-15.04,-4.63）,Z = 3.71,P = 0.000 2]和控制血糖[WMD = -0.33,95％CI（-0.72,0.06）,Z = 1.65,P = 0.100]水平对照组疗效相当。结论：参芪降糖颗粒（胶囊）治疗糖尿病肾病明显优于常规治疗。但由于高质量的文献很少,样本量有限,仍需进一步做深入研究。     

补阳还五汤联合贝那普利治疗早期糖尿病肾病临床疗效观察

目的：探讨补阳还五汤联合贝那普利治疗早期糖尿病肾病的临床疗效。方法：选取早期糖尿病肾病患者50例,随机分为对照组20例和治疗组30例,对照组给予口服贝那普利治疗,治疗组在对照组治疗的基础上给予补阳还五汤治疗,治疗2个月后比较两组疗效。结果：治疗组总有效率为96．7％,明显高于对照组的85．0％（P〈0．05）。结论：补阳还五汤联合贝那普利治疗早期糖尿病肾病疗效优于单用贝那普利治疗,值得临床推广应用。     

基于网络药理学探讨芪术颗粒治疗糖尿病肾病的作用机制

目的:运用网络药理学的方法,探索芪术颗粒治疗糖尿病肾病的作用机制。方法:采用中药系统药理学数据库和分析平台(TCMSP),中医百科全书数据库(ETCM),以口服生物利用度和类药性为限定条件筛选出芪术颗粒中各药的化学成分及其蛋白靶点,并通过UniProt数据库将蛋白靶点规范为相应的基因名称;通过在线《人类孟德尔遗传》数据库(OMIM),疾病-基因数据库(DisGeNET),治疗靶标数据库(TTD),ETCM数据库检索糖尿病肾病的相关基因;两者取交集之后,通过蛋白质相互作用数据库(STRING)构建蛋白互作网络,使用Cytoscape分析网络的核心靶点,使用KOBAS 3.0数据库对相关靶点进行基因本体(GO)富集分析和京都基因与基因组百科全书(KEGG)通路富集分析。结果:从芪术颗粒中共得到化学成分93个,涉及到254个靶点,与糖尿病肾病相关的基因607个,取交集后确定了76个芪术颗粒治疗糖尿病肾病的靶标,包括蛋白激酶B1(Akt1),血管内皮生长因子α(VEGFA),白细胞介素(IL)-6,肿瘤坏死因子(TNF),丝裂原活化蛋白激酶1(MAPK1),基质金属蛋白酶(MMP)-9等核心靶点,经过GO分析和KEGG分析,芪术颗粒可以影响细胞对氮化合物的反应、调节活性氧代谢过程等生物过程,调控糖尿病并发症中的晚期糖基化终产物(AGE)/晚期糖基化终产物受体(RAGE)信号通路,流体剪切应力和动脉粥样硬化,IL-17信号通路,缺氧诱导因子-1(HIF-1)信号通路,TNF信号通路等通路。结论:芪术颗粒对糖尿病肾病的治疗作用可能是影响Akt1,VEGFA,IL-6,TNF,MAPK1,MMP-9等靶点,调控糖尿病并发症中的AGE/RAGE信号通路、流体剪切应力和动脉粥样硬化,IL-17信号通路,HIF-1信号通路,TNF信号通路等通路发挥的,可以为进一步的基础实验研究提供理论参考。     

尿毒清颗粒治疗糖尿病肾病相关机理研究进展

尿毒清颗粒已在临床中应用数十年,其通过对TGF-β1、nephrin、podocin蛋白、Cys C、NF-κB及VEGF的表达进行拮抗性干预,改善高糖、高脂、微炎症等危险状态,以保护肾小球内皮细胞、足细胞,防止肾小球硬化和间质纤维化,稳定肾功能,修复肾脏病理改变,减缓DN进展,其保护肾脏的作用机理非常明确,该药价格适中,并且适用于任何原因引起的慢性肾功能衰竭,长期服用较为安全。     

中医辨证治疗早期糖尿病肾病临床观察

[目的]观察中医辨证治疗早期糖尿病肾病疗效。[方法]本组48例患者采用常规治疗高优质低蛋白,低盐饮食,服用溶栓克糖胶囊(人参,黄芪,丹参,山药,水蛭,鹿茸,龟,黄精,地鳖虫,地龙,当归,杜仲适量成粉末筛分到胶囊中,每个胶囊含有粗药物0.3g)。观测糖化血红蛋白,甘油三酯(TG),C反应蛋白,MALB,白蛋白ALB。[结果]经2个月治疗后,显效22例;有效17例;无效9例。两者联合治疗不仅可以改善糖化血红蛋白,甘油三酯(TG),C反应蛋白,改善肾功能,并能显着降低MALB,白蛋白ALB。[结论]中医辨证治疗早期糖尿病肾病疗效显著,值得临床推广。     

渴络欣胶囊辅助治疗糖尿病肾病的荟萃分析

目的：系统评价渴络欣胶囊辅助治疗糖尿病肾病的临床疗效。方法：检索中国期刊全文数据库（CNKI）、中文科技期刊全文数据库维普资讯（VIP）、万方数据知识平台、PubMed、EmBase、the Cochrane Library发表的有关渴络欣胶囊辅助治疗糖尿病肾病的随机对照试验。检索时间为从建库至2019年1月。文献筛选、资料提取和纳入文献的偏倚风险评价均由2位研究者独立完成,结果采用Cochrane软件RevMan5.3软件进行分析。结果：7项随机对照试验的596名糖尿病肾病患者纳入荟萃分析,其中302例患者采用渴络欣胶囊联合西药治疗,294例患者采用常规西药治疗。渴络欣胶囊联合西药组在对患者肾功能的改善中,血清肌酐（Scr）[WMD = -4.75,95%CI（-8.23,-1.28）,P = 0.01],血尿素氮（BUN）[WMD = -29.89,95%CI（-45.07,-14.71）,P =0.0001],均优于单纯西药组,差异有统计学意义。此外,在西药常规治疗的基础上辅助应用渴络欣胶囊可以改善DN患者的α1-MG、TC、TG、LDL-C、FBG、β2-MG、UAER、UTP水平,起到肾脏功能保护作用。但对于患者HDL-C、ALB无改善作用。试验中没有报告不良事件。结论：渴络欣胶囊作为辅助药物可改善糖尿病肾病患者肾功能,但仍需要高质量的临床试验进一步支持验证。     

益肾活血汤联合西医治疗早期糖尿病肾病对照研究

[目的]观察益肾活血汤联合西医治疗早期糖尿病肾病的疗效。[方法]将92例早期糖尿病肾病患者,分为对照组和治疗组各46例。对照组临床常规方法进行治疗;治疗组在常规治疗的基础上加用益肾活血汤(药用生龙骨、生牡蛎、山药、黄芪等),随症加减,1剂/d,分早晚2次服用。治疗2个疗程后判定疗效。[结果]治疗组临床疗效优于对照组(P<0.05);尿蛋白和血糖改善幅度明显大于对照组(P<0.05);实际治疗时间明显短于对照组(P<0.05);治疗后症状复发率明显低于对照组(P<0.05);两组患者治疗过程中均没有出现不良反应。[结论]益肾活血汤联合西医对患有早期糖尿病肾病的患者进行治疗的临床效果非常明显。